209 related articles for article (PubMed ID: 35451176)
1. Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 years.
Estepp JH; Kalpatthi R; Woods G; Trompeter S; Liem RI; Sims K; Inati A; Inusa BPD; Campbell A; Piccone C; Abboud MR; Smith-Whitley K; Dixon S; Tonda M; Washington C; Griffin NM; Brown C
Pediatr Blood Cancer; 2022 Aug; 69(8):e29716. PubMed ID: 35451176
[TBL] [Abstract][Full Text] [Related]
2. A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.
Howard J; Hemmaway CJ; Telfer P; Layton DM; Porter J; Awogbade M; Mant T; Gretler DD; Dufu K; Hutchaleelaha A; Patel M; Siu V; Dixon S; Landsman N; Tonda M; Lehrer-Graiwer J
Blood; 2019 Apr; 133(17):1865-1875. PubMed ID: 30655275
[TBL] [Abstract][Full Text] [Related]
3. Systematic Review of Voxelotor: A First-in-Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease.
Han J; Saraf SL; Gordeuk VR
Pharmacotherapy; 2020 Jun; 40(6):525-534. PubMed ID: 32343424
[TBL] [Abstract][Full Text] [Related]
4. Model-informed drug development of voxelotor in sickle cell disease: Exposure-response analysis to support dosing and confirm mechanism of action.
Green ML; Savic RM; Tonda M; Jorga K; Washington CB
CPT Pharmacometrics Syst Pharmacol; 2022 Jun; 11(6):698-710. PubMed ID: 35447017
[TBL] [Abstract][Full Text] [Related]
5. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
Vichinsky E; Hoppe CC; Ataga KI; Ware RE; Nduba V; El-Beshlawy A; Hassab H; Achebe MM; Alkindi S; Brown RC; Diuguid DL; Telfer P; Tsitsikas DA; Elghandour A; Gordeuk VR; Kanter J; Abboud MR; Lehrer-Graiwer J; Tonda M; Intondi A; Tong B; Howard J;
N Engl J Med; 2019 Aug; 381(6):509-519. PubMed ID: 31199090
[TBL] [Abstract][Full Text] [Related]
6. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.
Howard J; Ataga KI; Brown RC; Achebe M; Nduba V; El-Beshlawy A; Hassab H; Agodoa I; Tonda M; Gray S; Lehrer-Graiwer J; Vichinsky E
Lancet Haematol; 2021 May; 8(5):e323-e333. PubMed ID: 33838113
[TBL] [Abstract][Full Text] [Related]
7. Modeling the public health impact of voxelotor in the management of sickle cell disease in France.
Galacteros F; Ethgen O; Beillat M
PLoS One; 2023; 18(9):e0291211. PubMed ID: 37703228
[TBL] [Abstract][Full Text] [Related]
8. Voxelotor for the treatment of sickle cell disease in pediatric patients.
Brown C; Tonda M; Abboud MR
Expert Rev Hematol; 2022 Jun; 15(6):485-492. PubMed ID: 35671094
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease.
Hutchaleelaha A; Patel M; Washington C; Siu V; Allen E; Oksenberg D; Gretler DD; Mant T; Lehrer-Graiwer J
Br J Clin Pharmacol; 2019 Jun; 85(6):1290-1302. PubMed ID: 30743314
[TBL] [Abstract][Full Text] [Related]
10. Voxelotor: A Novel Treatment for Sickle Cell Disease.
Herity LB; Vaughan DM; Rodriguez LR; Lowe DK
Ann Pharmacother; 2021 Feb; 55(2):240-245. PubMed ID: 32674605
[TBL] [Abstract][Full Text] [Related]
11. An expert review of voxelotor for the treatment of hemolytic anemia in patients with sickle cell disease: 'bridging the gap between laboratory data and patient related outcomes'.
Inusa BPD; Mnika K; Babiker S
Expert Rev Hematol; 2023; 16(8):585-591. PubMed ID: 37329253
[TBL] [Abstract][Full Text] [Related]
12. Voxelotor Treatment Interferes With Quantitative and Qualitative Hemoglobin Variant Analysis in Multiple Sickle Cell Disease Genotypes.
Rutherford-Parker NJ; Campbell ST; Colby JM; Shajani-Yi Z
Am J Clin Pathol; 2020 Oct; 154(5):627-634. PubMed ID: 32561909
[TBL] [Abstract][Full Text] [Related]
13. Urgent use of voxelotor in sickle cell disease when immediate transfusion is not safe.
Ferlis M; Lipato T; Roseff SD; Smith WR
Eur J Haematol; 2022 Nov; 109(5):586-589. PubMed ID: 35848827
[TBL] [Abstract][Full Text] [Related]
14. Patient perception of voxelotor treatment benefit in sickle cell disease.
Idowu M; Haque A; Williams EM; Sridhar A
J Investig Med; 2022 Jun; 70(5):1316-1319. PubMed ID: 35732337
[TBL] [Abstract][Full Text] [Related]
15. Voxelotor for the treatment of sickle cell disease.
Vissa M; Vichinsky E
Expert Rev Hematol; 2021 Mar; 14(3):253-262. PubMed ID: 33602029
[No Abstract] [Full Text] [Related]
16. Model-informed drug development of voxelotor in sickle cell disease: Population pharmacokinetics in whole blood and plasma.
Savic RM; Green ML; Jorga K; Zager M; Washington CB
CPT Pharmacometrics Syst Pharmacol; 2022 Jun; 11(6):687-697. PubMed ID: 35447014
[TBL] [Abstract][Full Text] [Related]
17. Blocking HbS Polymerization in SCD.
Lettre G
Cell; 2020 Mar; 180(5):819. PubMed ID: 32142671
[TBL] [Abstract][Full Text] [Related]
18. Real-world effectiveness of voxelotor for treating sickle cell disease in the US: a large claims data analysis.
Shah N; Lipato T; Alvarez O; Delea T; Lonshteyn A; Weycker D; Nguyen A; Beaubrun A; Agodoa I
Expert Rev Hematol; 2022 Feb; 15(2):167-173. PubMed ID: 35191358
[TBL] [Abstract][Full Text] [Related]
19. Acute venous thromboembolism after initiation of voxelotor for treatment of sickle cell disease.
Lemon N; Sterk E; Rech MA
Am J Emerg Med; 2022 May; 55():225.e1-225.e3. PubMed ID: 34991907
[TBL] [Abstract][Full Text] [Related]
20. Unique Hemoglobinopathy Pattern Following Treatment with Voxelotor.
Poventud-Fuentes I; Portillo TP; Olayinka L; Marcogliese AN; Tubman VN; Devaraj S
Ann Clin Lab Sci; 2023 Jul; 53(4):647-652. PubMed ID: 37625829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
